157 related articles for article (PubMed ID: 30916605)
21. The effects of VEGF-A-inhibitors aflibercept and ranibizumab on the ciliary body and iris of monkeys.
Ludinsky M; Christner S; Su N; Taubitz T; Tschulakow A; Biesemeier A; Julien-Schraermeyer S; Schraermeyer U
Graefes Arch Clin Exp Ophthalmol; 2016 Jun; 254(6):1117-25. PubMed ID: 27106625
[TBL] [Abstract][Full Text] [Related]
22. The sterility, stability and efficacy of repackaged ziv-aflibercept for intravitreal administration.
Juhong J; Pongsachareonnont PF; Somkijrungroj T; Mavichak A; Varadisai A; Chariyavilaskul P; Chatsuwan T; Suttichet TB; Kulvichit K
Sci Rep; 2022 Feb; 12(1):2971. PubMed ID: 35194061
[TBL] [Abstract][Full Text] [Related]
23. NONINFECTIOUS VITRITIS AFTER INTRAVITREAL INJECTION OF ANTI-VEGF AGENTS: Variations in Rates and Presentation by Medication.
Williams PD; Chong D; Fuller T; Callanan D
Retina; 2016 May; 36(5):909-13. PubMed ID: 27115856
[TBL] [Abstract][Full Text] [Related]
24. LONG-TERM PHYSICAL STABILITY, STERILITY, AND ANTI-VEGF BIOACTIVITY OF REPACKAGED BEVACIZUMAB IN 2-ML GLASS VIALS.
Peterson JS; Rockwell K; Scott IU; Ip MS; VanVeldhuisen PC; Blodi BA;
Retina; 2019 Sep; 39(9):1802-1809. PubMed ID: 29746405
[TBL] [Abstract][Full Text] [Related]
25. Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing.
Bakri SJ; Snyder MR; Pulido JS; McCannel CA; Weiss WT; Singh RJ
Retina; 2006; 26(5):519-22. PubMed ID: 16770257
[TBL] [Abstract][Full Text] [Related]
26. Aflibercept for age-related macular degeneration: a game-changer or quiet addition?
Browning DJ; Kaiser PK; Rosenfeld PJ; Stewart MW
Am J Ophthalmol; 2012 Aug; 154(2):222-6. PubMed ID: 22813448
[TBL] [Abstract][Full Text] [Related]
27. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy.
Zehetner C; Bechrakis NE; Stattin M; Kirchmair R; Ulmer H; Kralinger MT; Kieselbach GF
Invest Ophthalmol Vis Sci; 2015 May; 56(5):3279-86. PubMed ID: 26024110
[TBL] [Abstract][Full Text] [Related]
28. Effects of Intravitreal Aflibercept on Galectin-1 and Vascular Endothelial Growth Factor-A Plasma Levels in Patients with Diabetic Retinopathy.
Waltl I; Zehetner C; Seifarth C; Handle F; Kieselbach GF; Angermann R; Kralinger MT
Curr Eye Res; 2018 Mar; 43(3):368-375. PubMed ID: 29172741
[TBL] [Abstract][Full Text] [Related]
29. Ranibizumab and Aflibercept: Intraocular Pharmacokinetics and Their Effects on Aqueous VEGF Level in Vitrectomized and Nonvitrectomized Macaque Eyes.
Niwa Y; Kakinoki M; Sawada T; Wang X; Ohji M
Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6501-5. PubMed ID: 26447985
[TBL] [Abstract][Full Text] [Related]
30. Recovery of plasma vascular endothelial growth factor concentrations during aflibercept loading phase and after the transition to bimonthly treatment for neovascular age-related macular degeneration.
Roald AB; Aass HC; Moe MC
Br J Ophthalmol; 2015 Dec; 99(12):1610-3. PubMed ID: 25966740
[TBL] [Abstract][Full Text] [Related]
31. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration.
Wang X; Sawada T; Sawada O; Saishin Y; Liu P; Ohji M
Am J Ophthalmol; 2014 Oct; 158(4):738-744.e1. PubMed ID: 24973606
[TBL] [Abstract][Full Text] [Related]
32. Differences in the incidence of aflibercept-related sterile endophthalmitis according to types of disposable syringes used.
Kim M; Kim JT
Graefes Arch Clin Exp Ophthalmol; 2022 Apr; 260(4):1139-1145. PubMed ID: 34977967
[TBL] [Abstract][Full Text] [Related]
33. Safety and Bioavailability of Complete and Half-Dose Intravitreal Ziv-Aflibercept in an Experimental Model: Contralateral Eye Study.
Lashay A; Delrish E; Ashrafi E; Movassat M; Asadi-Amoli F; Dinarvand R; Abrishami M
Ophthalmic Surg Lasers Imaging Retina; 2019 Dec; 50(12):785-790. PubMed ID: 31877224
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab.
Schargus M; Kopp KT; Helbig C; Frings A; Winter G
Transl Vis Sci Technol; 2021 Aug; 10(9):21. PubMed ID: 34406342
[TBL] [Abstract][Full Text] [Related]
35. Aflibercept: A review of its effect on the treatment of exudative age-related macular degeneration.
Papadopoulos Z
Eur J Ophthalmol; 2019 Jul; 29(4):368-378. PubMed ID: 30813810
[TBL] [Abstract][Full Text] [Related]
36. Physician-Industry Interactions and Anti-Vascular Endothelial Growth Factor Use Among US Ophthalmologists.
Taylor SC; Huecker JB; Gordon MO; Vollman DE; Apte RS
JAMA Ophthalmol; 2016 Aug; 134(8):897-903. PubMed ID: 27356110
[TBL] [Abstract][Full Text] [Related]
37. The Effect of Syringe-Filling Technique on the Risk for Endophthalmitis after Intravitreal Injection of Anti-VEGF Agents.
Finkelstein M; Katz G; Zur D; Rubowitz A; Moisseiev E
Ophthalmologica; 2022; 245(1):34-40. PubMed ID: 34348344
[TBL] [Abstract][Full Text] [Related]
38. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
[TBL] [Abstract][Full Text] [Related]
39. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
[TBL] [Abstract][Full Text] [Related]
40. Association of Acute Endophthalmitis With Intravitreal Injections of Corticosteroids or Anti-Vascular Growth Factor Agents in a Nationwide Study in France.
Baudin F; Benzenine E; Mariet AS; Bron AM; Daien V; Korobelnik JF; Quantin C; Creuzot-Garcher C
JAMA Ophthalmol; 2018 Dec; 136(12):1352-1358. PubMed ID: 30242325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
